IL13RA2 and neoplasm: Intraparenchymal administration of GB-13 into orthotopically implanted patient-derived xenograft models of HGG was feasible, and a single therapeutic infusion of GB-13 using CED significantly ameliorated tumor burden and resulted in significant prolongation in survival of animals harboring IL-13Rα2-upregulated orthotopic xenografts, underscoring the promise of IL-13Rα2 targeting in the context of HGG with increased IL-13Rα2 expression.